<DOC>
	<DOCNO>NCT00020475</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . Combining vaccine therapy interleukin-2 may effective treatment metastatic melanoma eye . PURPOSE : Phase II trial study effectiveness vaccine therapy interleukin-2 treating patient metastatic melanoma eye .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Metastatic Melanoma Eye</brief_title>
	<detailed_description>OBJECTIVES : I . Determine clinical response patient metastatic ocular melanoma treat gp100:209-217 ( 210M ) antigen MART-1:26-35 ( 27L ) antigen emulsify Montanide ISA-51 . II . Determine clinical benefit interleukin-2 combination vaccine patient . PROTOCOL OUTLINE : Patients receive vaccine subcutaneously weekly . Treatment repeat every 4 week total 6 course absence disease progression unacceptable toxicity . Patients progressive disease may receive vaccine SC day 1 follow interleukin-2 IV 15 minute every 8 hour maximum 12 dos . Treatment repeat every 3 week least 4 course absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 15-25 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis metastatic ocular melanoma Progressive disease Measurable disease HLAA*201 positive Prior/Concurrent Therapy Biologic therapy : At least 3 week since prior biologic therapy Chemotherapy : At least 3 week since prior chemotherapy Endocrine therapy : At least 3 week since prior endocrine therapy No concurrent steroid therapy Radiotherapy : At least 3 week since prior radiotherapy Surgery : Not specify Patient Characteristics Age : 16 Performance status : ECOG 02 Life expectancy : More 3 month Hematopoietic : WBC least 3,000/mm3 Platelet count least 90,000/mm3 No coagulation disorder Hepatic : Bilirubin great 2.0 mg/dL AST/ALT le 3 time normal Hepatitis B surface antigen negative Renal : Creatinine great 2.0 mg/dL Cardiovascular : No major cardiovascular illness For interleukin2 ( IL2 ) therapy : No cardiac ischemia No myocardial infarction No cardiac arrhythmia Pulmonary : No major respiratory system illness For IL2 therapy : No obstructive restrictive pulmonary disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active systemic infection No autoimmune disease No primary secondary immunodeficiency abnormal lymphocyte count presence opportunistic infection</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2002</verification_date>
	<keyword>adult solid tumor</keyword>
	<keyword>body system/site cancer</keyword>
	<keyword>cancer</keyword>
	<keyword>extraocular extension melanoma</keyword>
	<keyword>eye cancer</keyword>
	<keyword>intraocular melanoma</keyword>
	<keyword>recurrent intraocular melanoma</keyword>
	<keyword>solid tumor</keyword>
	<keyword>stage , intraocular melanoma</keyword>
</DOC>